Cancer immunotherapy using virally transduced dendritic cells: Animal studies and human clinical trials

Expert Review of Vaccines

Volumn 5, Issue 5, 2006, Pages 717-732

  Mossoba, Miriam E ^b   Medin, Jeffrey A ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Adeno associated virus; Adenovirus; Canarypox virus; Cancer; Clinical trials; Dendritic cells; Fowlpox virus; Immunotherapy; Lentivirus; Onco retrovirus; Vaccinia virus

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; BCR ABL PROTEIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; GLYCOPROTEIN GP 100; HEMAGGLUTININ; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; IRINOTECAN; MELAN A; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; MUCIN 1; OVALBUMIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN P53; PROTEIN TRP2; RECOMBINANT GAMMA INTERFERON; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BREAST CANCER; CANARYPOX VIRUS; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; DNA MODIFICATION; DOSE RESPONSE; DRUG INHIBITION; DRUG RECEPTOR BINDING; FEVER; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; IMMUNOSURVEILLANCE; INJECTION SITE ERYTHEMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VITILIGO;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELLS, CULTURED; CLINICAL TRIALS; DENDRITIC CELLS; DEPENDOVIRUS; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LENTIVIRUS; MICE; NEOPLASMS; POXVIRIDAE; PRIMATES; RETROVIRIDAE; TRANSDUCTION, GENETIC;

EID: 33845871185     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.5.717     Document Type: Review

References (88)

1. Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon-γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556-7561 (1998).
2. Street SE, Cretney E, Smyth MJ. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 97, 192-197 (2001).
3. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon-γ. J. Exp. Med. 196, 129-134 (2002).
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002). • Provides an excellent overview of numerous types of interactions between tumor cells and the immune system.
5. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
6. Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest. New Drugs 23(5), 391-409 (2005).
7. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Ad. Exp. Med. Biol. 532, 253-268 (2003).
8. Steinman RM. Some interfaces of dendritic cell biology. APMIS 111(7-8), 675-697 (2003). • Offers a very detailed description of dendritic cell (DC) biology by one of the discoverers of DCs.
9. Vari F, Hart DN. Loading DCs with Ag. Cytotherapy 6(2), 111-121 (2004).
10. Liu KJ, Wang CC, Chen LT et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin. Cancer Res. 10(8), 2645-2651 (2004).
11. Lesterhuis WJ, de Vries IJ, Schuurhuis DH et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann. Oncol. 17(6), 974-980 (2006).
12. + progenitors and activated with type I interferon. J. Immunother. 28(5), 505-516 (2005).
13. Lee WC, Wang HC, Hung CF et al. Vaccination of adanced hepatocellular carcinoma patients with tumor lysatepulsed dendritic cells: a clinical trial. J. Immunother. 28(5), 496-504 (2005).
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 92, 205-216 (2000).
15. Jeong JG, Lee HJ, Ahn HS. Comparison of strategies for tumor antigen loading of dendritic cells: adenoviral vector and tumor lysate. J. Immunother. 28(6), 614 (2005).
16. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 106(3), 271-274 (2001).
17. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183(1), 283-287 (1996).
18. Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J. Immunother. 25(4), 289-303 (2002).
19. Markiewicz MA, Kast WM. Progress in the Development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest. 22(3), 417-434 (2004).
20. Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. 7, 2028-2035 (2000).
21. Milcho M, Serguei Z, Iskra A et al. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther. 10(12), 907-917 (2003).
22. O'Sullivan I, Ng LK, Martinez DM, Kim TS, Chopra A, Cohen EP. Immunity to squamous carcinoma in mice immunized with dendritic cells transfected with genomic DNA from squamous carcinoma cells. Cancer Gene Ther. 12, 825-834 (2005).
23. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109, 409-417 (2002).
24. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199, 251-263 (2004).
25. Edelstein ML, Abedi RM, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004 - an overview. J. Gene Med. 6, 597-602 (2004).
26. Kikuchi T. Genetically modified dendritic cells for therapeutic immunity. Tohoku J. Exp. Med. 208(1), 1-8 (2006).
27. Molinier-Frenkel V, Prevost-Blondel A, Hong SS et al. The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain. J. Biol. Chem. 278(39), 175-182 (2003).
28. Tillman BW, de Gruijl TD, Luykx-de Bakker SA et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162(11), 6378-6383 (1999).
29. Sili U, Huls MH, Davis AR et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J. Immunother. 26(3), 241-256 (2003).
30. Shayakhmetov DM, Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. J. Virol. 74(22), 10274-10286 (2000).
31. Pastoreta PP, Vanderplasschen A. Poxviruses as vaccine vectors. Comp. Immunol. Microb. Infect. Dis. 26, 343-355 (2003).
32. Drillien R, Spehner D, Bohbot A, Hanau D. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology 268, 471-481 (2000).
33. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Exp. Opinion Biol. Ther. 4(4), 575-588 (2004).
34. Barquinero J, Eixarch H, Perez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther. 11(Suppl. 1), S3-S9 (2004).
35. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5), 346-358 (2003).
36. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol. 21(3), 117-122 (2003).
37. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644), 415-419 (2003).
38. Ponnazhagan S, Curiel DT, Shaw DR, Alvarez RD, Siegal GP. Adeno-associated virus for cancer gene therapy. Cancer Res. 61, 6313-6321 (2001).
39. Steitz J, Tormo D, Schweichel D, Tuting T. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. Cancer Gene Ther. 13, 318-325 (2006).
40. Broder H, Anderson A, Kremen TJ, Odesa SK, Liau LM. MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor. J. Neuro-Oncol. 64, 21-30 (2003).
41. Okada N, Masunaga Y, Okada Y et al. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Ther. 10, 1891-1902 (2003).
42. Sakai Y, Morrison BJ, Burke JD et al. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 64, 8022-8028 (2004).
43. Murakami T, Tokunaga N, Waku T et al. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene. Clin. Cancer Res. 3871(10), 3871-3880 (2004).
44. Tatsumi T, Huang J, Gooding WE et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 63(19), 6378-6386 (2003).
45. Montoya M, Schiavoni G, Mattei F et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99, 3263-3271 (2002).
46. Kuwashima N, Nishimura F, Eguchi J et al. Delivery of dendritic cells engineered to secrete IFN-α into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J. Immunol. 175(4), 2730-2740 (2005).
47. Medin JA, Liang SB, Whit-Shan Hou J, Kelley LS, Peace DJ, Fowler DH. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther. 12, 540-551 (2005).
48. Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 96, 1327-1333 (2000).
49. Tan PH, Beutelspacher SC, Xue SA et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 105(10), 3824-3832 (2005).
50. He Y, Zhang J, Mi Z, Robbins P, Falo LD Jr. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J. Immunol. 174, 3808-3817 (2005).
51. Metharom P, Ellem K, Schmidt C, # Wei M. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum. Gene Ther. 12, 2203-2213 (2001).
52. Cui Y, Kelleher E, Straley E et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat. Med. 9(7), 952-958 (2003).
53. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22, 1546-1553 (2004). •• Demonstrates a novel method of enhancing antigen presentation for augmenting antitumor immune responses in a mouse model.
54. Kung SP, Bonifacino A, Metzger ME, Ringpis GE, Donahue RE. Lentiviral vector-transduced dendritic cells induce specific T cell response in a nonhuman primate model. Hum. Gene Ther. 16, 527-532 (2005).
55. Bai L, Feuerer P, Beckhove V, Umansky V, Schirrmacher V. Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells. Int. J. Oncol. 20, 247-253 (2002).
56. Frolkisa M, Fischera MB, Wang Z, Lebkowski JS, Chiu CP, Majumdar AS. Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors. Cancer Gene Ther. 10, 239-249 (2003).
57. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. 4, 43-49 (1998).
58. Maruyama K, Akiyama Y, Nara-Ashizawa N et al. Adenovirusmediated MUC1 gene transduction into human blood-derived dendritic cells. J. Immunother. 24(4), 345-353 (2001).
59. Schumacher L, Ribas A, Dissette VB et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J. Immunother. 27(3), 191-200 (2004).
60. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res. 6523(9), 6523-6533 (2003).
61. Nikitina EY, Clark JI, Van Beynen J et al. Dendritic cells transduced with fulllength wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin. Cancer Res. 7(1), 127-135 (2001).
62. Meyer zum Buschenfelde C, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J. Immunol. 167, 1712-1719 (2001).
63. Firat H, Zennou V, Garcia-Pons F et al. Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J. Gene Med. 4, 38-45 (2002).
64. Breckpot K, Dullaers M, Bonehill A et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J. Gene Med. 5, 654-667 (2003).
65. Liu Y, Chiriva-Internati M, You C et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. Cancer Gene Ther. 12, 304-312 (2005).
66. Sun J-Y, Krouse RS, Forman SJ et al. Immunogenicity of a p210BCR-ABL fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res. 62, 3175-3183 (2002).
67. Chiriva-Internati M, Liu Y, Salati E et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur. J. Immunol. 32, 30-38 (2002).
68. Chiriva-Internati M, Liu Y, Weidanz JA et al. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 102, 3100-3107 (2003).
69. Motta I, Andre F, Lim A et al. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant Canarypox virus-infected dendritic cells. J. Immunol. 167, 1795-1802 (2001).
70. Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol. Immunother. 50(8), 397-407 (2001).
71. Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12(3 Pt 1), 878-887 (2006). •• Illustrates the benefit of merging DC-mediated immunotherapy with a conventional treatment modality in a clinical setting.
72. +-derived dendritic cell vaccination: a Phase I trial in metastatic melanoma. Clin. Cancer Res. 10(16), 5381-5390 (2004).
73. Morse MA, Clay TM, Hobeika AC et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res. 11(8), 3017-3024 (2005).
74. Walker PR, Calzascia T, de Tribolet N, Dietrich PY. T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res. Rev. 42(2), 97-122 (2003).
75. Wekerle H. Breaking ignorance: the case of the brain. Curr. Top. Microbiol. Immunol. 305, 25-50 (2006).
76. Barratt-Boyes SM, Figdor CG. Current issues in delivering DCs for immunotherapy. Cytotherapy 6(2), 105-110 (2004).
77. Pirtskhalaishvili G, Shurin GV, Gambotto A et al. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J. Immunol. 165(4), 1956-1964 (2000).
78. Ojima T, Iwahashi M, Nakamura M et al. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Int. J. Oncol. 28(4), 947-953 (2006).
79. Teitz-Tennenbaum S, Li Q, Rynkiewicz S et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res. 63(23), 8466-8475 (2003).
80. Chi KH, Liu SJ, Li CP et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J. Immunother. 28(2), 129-135 (2005).
81. Baecher-Allan C, Anderson DE. Immune regulation in tumor-bearing hosts. Curr. Opin. Immunol. 18(2), 214-219 (2006).
82. + T cell-mediated suppression by dendritic cells. Science 299, 1033-1036 (2003).
83. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5, 508-515 (2004). •• Reveals an important mechanism by which DCs can help overcome a tolerant environment.
84. + T cells. Immunity 19(6), 877-889 (2003).
85. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin Invest. 115(12), 3623-3633 (2005). •• Provides a good example of how reducing the levels of regulatory T cells in cancer patients can improve the antitumor effects of immunotherapy.
86. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263-274 (2005).
87. + T cell response in cancer immunotherapy. J. Gene Med. 7(6), 686-695 (2005).
88. Dropulic B, AkkinaR, Infectious Disease Committee. American Society of Gene Therapy 8th annual meeting highlights (2005). Infectious Disease Symposium. ww.asgt.org/am05/asgt_news/highlights2.html